Article
Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53.
Advances in biological regulation - 1 Jan 2021
Abrams Stephen L, Akula Shaw M, Martelli Alberto M, Cocco Lucio, Ratti Stefano, Libra Massimo, Candido Saverio, Montalto Giuseppe, Cervello Melchiorre, Gizak Agnieszka, Rakus Dariusz, Steelman Linda S, McCubrey James A
Abstract excerpt
Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic malignancy. Approximately 85% of pancreatic cancers are classified as PDACs. The survival of PDAC patients is very poor and only 5-10% of patients survive 5 years after diagnosis. Mutations at the KRAS and TP53 gene are frequently observed in PDAC patients. The PANC-28 cell line lacks wild-type (WT) TP53. In the following study, we have investigated...
Topics
- Antineoplastic Agents
- Cell Proliferation
- Dietary Supplements
- Female
- Humans
- Male
- Mutation
- Pancreatic Neoplasms
- Proto-Oncogene Proteins p21(ras)